Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan vs BSC in Second-Line Gastric Cancer
NCT00144378Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric cancer (GC) and gastroesophageal junction adenocarcinoma comparing Irinotecan with Best Supportive Care (2 arms). Primary endpoint: Overall Survival. Started Oct 2002; status: completed.
02
Drugs
irinotecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00144378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144378.